Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Study highlights economic complications of esketamine for depressive disorders

Staff Writer
Staff Writer 2 years ago
Updated 2020/07/20 at 11:12 PM
Share
SHARE

New research in the journal Psychiatric Services highlights the complications of esketamine for patients with depressive disorders.

According to researchers, the recently approved general anesthetic for treatment-resistant depression, marketed and sold as a form of nasal spray, may be too costly for a substantial amount of the general population.

“Esketamine has been effective in a population where many other treatments haven’t worked,” said Eric Ross, the study’s lead author, in a news release. “I want people to use esketamine, but it’s important that it be cost-effective. I don’t want it to put a real strain on our mental health care system.”

The study used a decision-analytic model to simulate the effects of the esketamine drug treatment in comparison to conventional antidepressants over a span of five years.

Based on their findings, it was purportedly found that esketamine, although refuted by a few health organizations and regarded as ineffective, significantly improved quality of life over time. However, societal costs and health care sector costs are expected to surge, drawing complications for patients in need of an effective treatment even as other pharmaceutical options fail.

“The authors estimated a greater than 95% likelihood that intranasal esketamine would not be cost-effective in the United States, according to commonly applied standards,” Ross explained.

“Esketamine is too expensive, but it does work,” Ross implied. “The question now is ‘How do we get the price down?'”

You Might Also Like

Study finds vitamin D does not reduce risk of type 2 diabetes

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

Study finds no structural brain change during mindfulness-based stress training

Study finds diet may be a contributing factor in ADHD symptoms associated in children

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

TAGGED: esketamine, depressive disorders
Staff Writer July 18, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article How researchers used smartphone data to gain insight into a user’s personality
Next Article Researchers corrected mutations through RNA repair, paving the way for potential Rett syndrome treatments

Recommended

Clinical

Study finds vitamin D does not reduce risk of type 2 diabetes

2 Min Read
Clinical

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

1 Min Read
Clinical

Study finds no structural brain change during mindfulness-based stress training

1 Min Read
Clinical

Study finds diet may be a contributing factor in ADHD symptoms associated in children

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?